UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of $516.26 million. The enterprise value is $399.47 million.

Market Cap	516.26M
Enterprise Value	399.47M

Important Dates

The last earnings date was Monday, March 10, 2025, before market open.

Earnings Date	Mar 10, 2025
Ex-Dividend Date	n/a

Share Statistics

UroGen Pharma has 46.09 million shares outstanding. The number of shares has increased by 48.70% in one year.

Current Share Class	46.09M
Shares Outstanding	46.09M
Shares Change (YoY)	+48.70%
Shares Change (QoQ)	+9.12%
Owned by Insiders (%)	5.07%
Owned by Institutions (%)	72.48%
Float	36.99M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.31
Forward PS	3.95
PB Ratio	-58.65
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.01

Current Ratio	6.01
Quick Ratio	5.59
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.64

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-25.78%
Return on Invested Capital (ROIC)	-79.15%
Return on Capital Employed (ROCE)	-39.91%
Revenue Per Employee	$384,672
Profits Per Employee	-$539,889
Employee Count	235
Asset Turnover	0.39
Inventory Turnover	1.19

Taxes

In the past 12 months, UroGen Pharma has paid $2.83 million in taxes.

Income Tax	2.83M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.13% in the last 52 weeks. The beta is 1.12, so UroGen Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.12
52-Week Price Change	-25.13%
50-Day Moving Average	10.66
200-Day Moving Average	12.80
Relative Strength Index (RSI)	53.20
Average Volume (20 Days)	415,309

Short Selling Information

The latest short interest is 6.15 million, so 13.34% of the outstanding shares have been sold short.

Short Interest	6.15M
Short Previous Month	6.12M
Short % of Shares Out	13.34%
Short % of Float	16.63%
Short Ratio (days to cover)	15.35

Income Statement

In the last 12 months, UroGen Pharma had revenue of $90.40 million and -$126.87 million in losses. Loss per share was -$2.96.

Revenue	90.40M
Gross Profit	81.52M
Operating Income	-95.68M
Pretax Income	-100.36M
Net Income	-126.87M
EBITDA	-95.35M
EBIT	-95.68M
Loss Per Share	-$2.96

Full Income Statement

Balance Sheet

The company has $236.69 million in cash and $124.92 million in debt, giving a net cash position of $116.79 million or $2.53 per share.

Cash & Cash Equivalents	236.69M
Total Debt	124.92M
Net Cash	116.79M
Net Cash Per Share	$2.53
Equity (Book Value)	-8.80M
Book Value Per Share	-0.21
Working Capital	230.19M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$96.77 million and capital expenditures -$295,000, giving a free cash flow of -$97.06 million.

Operating Cash Flow	-96.77M
Capital Expenditures	-295,000
Free Cash Flow	-97.06M
FCF Per Share	-$2.11

Full Cash Flow Statement

Margins

Gross margin is 90.18%, with operating and profit margins of -105.85% and -140.35%.

Gross Margin	90.18%
Operating Margin	-105.85%
Pretax Margin	-137.22%
Profit Margin	-140.35%
EBITDA Margin	-105.48%
EBIT Margin	-105.85%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.70%
Shareholder Yield	n/a
Earnings Yield	-24.58%
FCF Yield	-18.80%

Analyst Forecast

The average price target for UroGen Pharma is $40.75, which is 263.84% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$40.75
Price Target Difference	263.84%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	57.42%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -2.68 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.68
Piotroski F-Score	3